Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425347 · ClinicalTrials.gov registry record · Phase 1
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
A Phase 1 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00425347 is a Phase 1 study that has completed, run by Facet Biotech. The registered enrollment target is 35 participants.
The verdict
NCT00425347, a Phase 1 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.
Interventions
- DRUG HuLuc63
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425347
The ClinicalTrials.gov registry entry for NCT00425347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HuLuc63 is the first listed.
NCT00425347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425347 about?
NCT00425347 is a clinical study titled "Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma". To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.
What is the current status of trial NCT00425347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2006-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00425347?
The interventions under investigation include: HuLuc63 (DRUG).
Who is sponsoring clinical trial NCT00425347?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.